https://www.selleckchem.com/pr....oducts/sp-600125.htm
Cytomegalovirus DNAemia was not statistically different between those receiving weight-based vs FDA-approved valganciclovir dosing; however, patients receiving the FDA-approved dosing were more likely to develop neutropenia. Among the intermediate-risk group, the adjusted relative risk of CMV DNAemia was 0.62 (95% CI, 0.36-1.09) for those not receiving chemoprophylaxis compared with those who did. Risk of CMV DNAemia is higher among patients receiving valganciclovir for 150 days. Further exploration of weight-based valganciclovir
Like
Comment
Share
